Spinogenix Reveals Promising Phase 2a Results for SPG302, Innovative ALS Treatment Spinogenix announces encouraging topline results from its Phase 2a trial of SPG302, a groundbreaking ALS treatment, showcasing significant potential.

Spinogenix Reveals Promising Phase 2a Results for SPG302, Innovative ALS Treatment #United_States #Los_Angeles #ALS_Treatment #Spinogenix #SPG302

Spinogenix's Latest Study Reveals SPG302 as a Breakthrough Neuroprotective Treatment for Glaucoma Spinogenix has published promising results from a study highlighting the potential of SPG302 in protecting retinal cells from glaucoma. The findings illuminate a new therapeutic direction.

Spinogenix's Latest Study Reveals SPG302 as a Breakthrough Neuroprotective Treatment for Glaucoma #United_States #Los_Angeles #Spinogenix #glaucoma #SPG302

Spinogenix Reports Promising Results on SPG302 for Alzheimer’s Disease Treatment Spinogenix, Inc. shares positive findings from its Phase 2a trial of SPG302, a pioneering treatment for Alzheimer's disease, showcasing rapid cognitive improvement and a strong safety profile.

Spinogenix Reports Promising Results on SPG302 for Alzheimer’s Disease Treatment #United_States #Los_Angeles #Alzheimer's_Disease #Spinogenix #SPG302

Spinogenix Achieves Full Enrollment in SPG302 Phase 2 Trial for Alzheimer's Therapy Spinogenix has successfully completed full enrollment for its Phase 2 clinical trial of SPG302, aimed at treating Alzheimer's disease. Results will be shared soon.

Spinogenix Achieves Full Enrollment in SPG302 Phase 2 Trial for Alzheimer's Therapy #Los_Angeles #Australia #Alzheimer's_Disease #Spinogenix #SPG302

Spinogenix's SPG302: A Hopeful Treatment Breakthrough for ALS Patients Spinogenix, Inc. has received orphan drug designation from the EMA for SPG302, a promising therapeutic for ALS, aiming to restore synapses and improve patient quality of life.

Spinogenix's SPG302: A Hopeful Treatment Breakthrough for ALS Patients #United_States #Los_Angeles #ALS #Spinogenix #SPG302

Spinogenix Launches Expanded Access Program for Groundbreaking ALS Treatment SPG302 Spinogenix has announced an FDA-authorized Expanded Access Program for SPG302, a revolutionary treatment aimed at improving conditions for ALS patients, providing hope and innovative solutions.

Spinogenix Launches Expanded Access Program for Groundbreaking ALS Treatment SPG302 #United_States #Los_Angeles #ALS #Spinogenix #SPG302

Spinogenix Unveils Phase 2 Trial Enrollment for SPG302 as Revolutionary Therapy for Schizophrenia Spinogenix, Inc. has announced the commencement of Phase 2 patient enrollment for SPG302, marking a significant step in the treatment of schizophrenia through synaptic regeneration.

Spinogenix Unveils Phase 2 Trial Enrollment for SPG302 as Revolutionary Therapy for Schizophrenia #United_States #Los_Angeles #schizophrenia #Spinogenix #SPG302